Since MC180295 could suppress the expression of BRCA1 and BRCA2, DNA damage response for double-stranded DNA breaks was disrupted in the MC180295-treated EBVaGC cells, indicating that the combination of MC190285 and a PARP inhibitor might lead to cancer-cell-specific death. The gene discussed is BRCA2; the disease is cancer.